---
schema_version: "secwatch.filing_event.v1"
accession: "0001778922-26-000033"
form_type: "8-K"
ticker: "SGP"
cik: "0001778922"
company_name: "SpyGlass Pharma, Inc."
filed_at: "2026-05-14T20:15:16+00:00"
generated_at: "2026-05-14T20:53:35.722937+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# SpyGlass Pharma reports Q1 loss of $13.8M; Phase 1/2 BIM-IOL data shows 98% drop-free, 34% IOP reduction

## Summary
- Net loss of $13.8M ($0.69/share) vs $8.8M loss in Q1 2025; R&D expenses $8.5M, G&A $6.9M.
- Cash & investments $251M as of Mar 31, 2026, funded through 2028 after $172.5M IPO in Feb 2026.
- Phase 1/2 BIM-IOL 12-mo data: 98% drop-free, 34% mean IOP reduction from baseline at 78-mcg dose.
- Phase 3 registrational trials SGP-005 and SGP-006 continue; enrollment completion expected in 2027.
- Bimatoprost Drug Ring (BIM-DRS) first-in-human trial on track to start H2 2026.

## SEC filing metadata
- accession: 0001778922-26-000033
- form_type: 8-K
- ticker: SGP
- cik: 0001778922
- company_name: SpyGlass Pharma, Inc.
- filed_at: 2026-05-14T20:15:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000033/0001778922-26-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000033/sgp-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001778922-26-000033
- JSON: https://secwatch.observer/filing/0001778922-26-000033.json
- Plain text: https://secwatch.observer/filing/0001778922-26-000033.txt

## Key facts
- Earnings Releases
  SpyGlass Pharma, Inc. reported first quarter ended March 31, 2026 results: net income $13.8 million, EPS ($0.69) per basic and diluted share.
  - Period: first quarter ended March 31, 2026
  - Net income: $13.8 million
  - EPS: ($0.69) per basic and diluted share
  - Result: reported results
  source text: Net Loss was $13.8 million, or ($0.69) per basic and diluted share, for the first quarter of 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000033/0001778922-26-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.